Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...

About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body.

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers through ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American ...

SEATTLE, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a ...